PATIENT-REPORTED OUTCOMES WITH UPADACITINIB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: PHASE 2 RESULTS FROM CELEST STUDY

Laurent Peyrin-Biroulet  1     Edouard Louis  2     Edward V Loftus Jr  3     Namita Tundia  4     Mahesh Fuldeore  4     Ana P. Lacerda  4     Jeffrey Enejosa  5     Aileen L Pangan    
1 Nancy University Hospital,Les Nancy,France
2 University Hospital CHU of Liège,Liège,Belgium
3 Mayo Clinic College of Medicine,Rochester,United States of America
4 AbbVie Inc.,North Chicago,United States of America
5 AbbVie Inc.,North C

Conference
25th UEG Week 2017

Citation
United European Gastroenterology Journal 2017; 5 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing